To the full analysis
Elevance Health stock: growth
ELVElevance Health reported $199.13B in revenue for fiscal 2025, up 12.6% on the prior year, up 10.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.8%
per year from 2006 to 2025, per share 12.8%
Earnings (Annual rate)
3.2%
per year from 2006 to 2025, per share 9%
Free cash flow (Annual rate)
−1%
per year from 2006 to 2025, per share 4.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 10.3% | 9.7% | 6.8% |
| Revenue per share | 13.1% | 11.5% | 12.8% |
| Earnings | 4.4% | 8.3% | 3.2% |
| Earnings per share | 6.7% | 10.0% | 9.0% |
| Free cash flow | −20.0% | −1.0% | −1.0% |
| Free cash flow per share | −18.0% | 0.6% | 4.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $57.01B | $3.09B | $3.85B |
| 2007 | $61.39B | $3.35B | $4.02B |
| 2008 | $62.46B | $2.49B | $2.19B |
| 2009 | $61.64B | $4.75B | $2.66B |
| 2010 | $58.84B | $2.89B | $965.3M |
| 2011 | $60.8B | $2.65B | $2.85B |
| 2012 | $61.54B | $2.66B | $2.2B |
| 2013 | $71.12B | $2.65B | $2.45B |
| 2014 | $73.92B | $2.57B | $2.74B |
| 2015 | $79.24B | $2.56B | $3.51B |
| 2016 | $84.98B | $2.47B | $2.62B |
| 2017 | $90.04B | $3.84B | $3.39B |
| 2018 | $92.11B | $3.75B | $2.62B |
| 2019 | $104.21B | $4.81B | $4.98B |
| 2020 | $121.87B | $4.57B | $9.67B |
| 2021 | $138.64B | $6.1B | $7.28B |
| 2022 | $156.6B | $5.89B | $7.25B |
| 2023 | $171.34B | $5.99B | $6.77B |
| 2024 | $176.81B | $5.98B | $4.55B |
| 2025 | $199.13B | $5.66B | $3.17B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026, previously Strong
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.